FOR IMMEDIATE RELEASE

Global Media Contacts:

David Schull or Lena Evans
Russo Partners
+1 212-845-4271
+1 212-845-4262
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com

David Kujawa
OrbusNeich
+1 954-730-0711 (office)
+1 305-733-7216 (mobile)
dkjawa@orbusneich.com

OrbusNeich’s COMBO Dual Therapy Stent™ to be Featured in Multiple Clinical Data Presentations Next Week at TCT 2012

Company Will Also Introduce Its Design of a Fully Drug Eluting Bioabsorbable Scaffold with Endothelial Progenitor Cell (EPC) Capture Technology

HONG KONG, Oct. 16, 2012 – OrbusNeich today announced that multiple presentations of clinical data for the COMBO Dual Therapy Stent will take place next week at TCT 2012 in Miami Beach.

The scientific sessions will feature cumulative results from the REMEDEE study (Randomized Evaluation of an abluMinial sirolimus coatED bio-Engineered stEnt), a randomized trial of the COMBO Dual Therapy Stent versus a drug eluting stent, and data from the REMEDEE OCT and EGO COMBO studies to assess the healing profile of COMBO compared to a drug eluting stent by optical coherence tomography (OCT). Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, will deliver the oral presentation “REMEDEE Combo (OrbusNeich) Program Update” during the session “Metallic Drug-Eluting Stents with
Bioabsorbable Polymers” at 2:37 p.m. EDT on Tuesday, Oct. 23, in Hall A/Coronary Theater at the Miami Beach Convention Center.

In addition, posters featuring the COMBO Dual Therapy Stent will be displayed from 8 a.m. to 10 a.m. EDT on Tuesday, Oct. 23, in Hall D. The principal investigators will be available during that time to answer physicians’ questions. Specifically, the posters will be:

- “The REMEDEE OCT Study: A Prospective Randomized Study of the Early Vascular Healing of a Novel Dual Therapy Stent in Comparison with an Everolimus-Eluting Stent,” (TCT-282), presented by Ulf Landmesser, M.D., Ph.D., of the Cardiovascular Center, University Hospital of Zürich, Switzerland

- “Evaluation of Neointimal Healing and Late Luminal Loss of Endothelial Progenitor Cell Capturing Sirolimus-Eluting (COMBO) Stent by Optical Coherence Tomography: The EGO-COMBO Study,” (TCT-292), presented by Stephen W.L. Lee, M.D., of the Queen Mary Hospital, University of Hong Kong, China

At 7 a.m. EDT on Thursday, Oct. 25, in room C223-224, a breakfast symposium entitled “OrbusNeich’s COMBO Dual Therapy Stent: Addressing the Limitations of Drug Eluting Stents” will be chaired by Prof. Lee and Roxana Mehran, M.D., of Mount Sinai Medical Center, New York. Dr. Mehran will open the symposium with a discussion of the challenge facing today’s practicing cardiologist – balancing bleeding and ischemic events. Prof. Haude will present results from the REMEDEE study, while Jonathan M. Hill, M.D., of the King's College Hospital, London, will discuss modes of assessing the effect of EPC capture on vascular healing. Prof. Lee will then discuss results from the EGO COMBO study, and Dr. Landmesser will present the study design and preliminary results of REMEDEE OCT.

Also at TCT 2012, Robert Cottone, OrbusNeich’s vice president of intellectual property & technologies, will present “Design of a Fully Drug-Eluting Bioabsorbable Scaffold with EPC-Capture Technology” at 5:52 p.m. EDT on Tuesday, Oct. 23, in Hall A/Coronary Theater during the session “Bioresorbable Vascular Scaffolds: Latest Designs and Clinical Study Evidence.”
About the COMBO Dual Therapy Stent

The COMBO Dual Therapy Stent is the first dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the proven pro-healing technology with an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days.

OrbusNeich’s patented EPC capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the COMBO Dual Therapy Stent, the world’s first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich’s YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

###